Browse News
Filter News
Found 147 articles
-
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
11/27/2023
Annovis Bio, Inc. announced that AD phase II/III study of its lead compound buntanetap has exceeded full enrollment.
-
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
11/8/2023
Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced third quarter financial results for the period ended September 30, 2023, and reviewed recent accomplishments.
-
Annovis Bio Announces Pricing of $7.5 Million Public Offering
10/31/2023
Annovis Bio, Inc. announced the pricing of an underwritten public offering of 1,250,000 units consisting of one share of its common stock and an accompanying warrant.
-
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
10/30/2023
Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease (AD) patients.
-
Annovis Bio Announces Launch of Proposed Public Offering - October 30, 2023
10/30/2023
Annovis Bio, Inc., a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and an accompanying warrant to purchase shares of common stock.
-
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
10/24/2023
Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 annual conference held in Boston, Massachusetts, from October 24-27.
-
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
10/12/2023
Annovis Bio, Inc. today announced that the independent statistical group concluded that its Phase 2/3 AD study was sufficiently powered to continue as originally planned without the addition of patients.
-
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8/15/2023
Annovis Bio, Inc. announced second quarter financial results for the period ended June 30, 2023, and reviewed recent accomplishments.
-
BioSpace rounded up companies with products for Alzheimer’s, ALS, Parkinson’s and Huntington’s in the final stages of clinical testing.
-
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
7/18/2023
Annovis Bio, Inc. (NYSE: ANVS ), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), presented three posters at the Alzheimer’s Association International Conference (AAIC) 2023 annual meeting held in Amsterdam, Netherlands, from July 16-20.
-
Annovis Bio Announces the Filing of a Groundbreaking Patent
6/27/2023
Annovis Bio, Inc. announces the creation of a novel crystalline form of buntanetap (ANVS402), and the filing of a new composition of matter provisional patent with the U.S. Patent and Trademark Office.
-
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
6/20/2023
Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for early Parkinson’s Disease (PD) patients.
-
Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace
6/8/2023
Annovis Bio, Inc. announced that its PD phase III study of its lead compound buntanetap has reached full enrollment in a record nine months after it began.
-
Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
5/11/2023
Annovis Bio, Inc. announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments.
-
While donanemab showed impressive results in Phase III TRAILBLAZER-ALZ 2, concerns regarding its safety remain compared with Biogen’s and Eisai’s Leqembi.
-
Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
4/27/2023
Annovis Bio announced that the United States Patent and Trademark Office has granted the Company a patent with claims covering the use of Annovis Bio’s lead drug candidate, buntanetap, for the prevention and treatment of diseases caused by the disruption in heavy metal homeostasis.
-
ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST
4/20/2023
Annovis Bio, Inc is providing an updated link and dial-in information for the Company's R&D Webcast scheduled for today at 4:00 pm ET.
-
ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST
4/19/2023
Annovis Bio, Inc. today announced that patient recruitment for the Company's Phase 2/3 study of buntanetap for the treatment of moderate Alzheimer's disease (AD) remains consistent with its planned development program.
-
ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS
4/13/2023
Annovis Bio, Inc. today announced that the Company will hold a live R&D webcast to review its clinical development programs in Alzheimer's disease and Parkinson's disease.
-
ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION
4/11/2023
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company") today announced that in the last week it has raised aggregate gross proceeds of approximately $8.7 million between its now-terminated at–the-market program and a private placement to individual members of its Board of Directors and management.